Monitoring of MYD88 L265P mutation by droplet digital polymerase chain reaction for prediction of early relapse in a patient with Bing-Neel syndrome.

International Journal of Hematology
Hisaharu ShikataKeiichiro Hattori

Abstract

Bing-Neel syndrome (BNS) is a rare neurologic complication of lymphoplasmacytic lymphoma (LPL) characterized by direct infiltration of lymphoplasmacytic cells (LPCs). Although no standard treatment has yet been established, patients with BNS harboring the MYD88 L265P mutation have been reported to respond favorably to ibrutinib, which can cross the blood-brain barrier and trigger apoptosis of MYD88 L265P-positive LPCs. However, it is still unclear whether monitoring of MYD88 L265P mutation status would be useful for predicting relapse/progression or for assisting diagnosis and evaluating response to chemotherapy. Here, we report the case of a patient with BNS receiving ibrutinib in whom we detected relapse early by monitoring for molecular residual disease (MRD) based on the presence of the MYD88 L265P mutation in cerebrospinal fluid (CSF) on droplet digital polymerase chain reaction assay. Persistent MRD increased 2 weeks before the onset of relapse symptoms without any abnormal imaging findings or evidence of clonal LPCs on CSF cytology, flow cytometry analysis, or immunofixation electrophoresis. Our findings suggest that an increase in MRD levels is correlated with relapse in patients with BNS.

References

Aug 28, 2014·British Journal of Haematology·Stéphanie PoulainXavier Leleu
Jul 14, 2016·British Journal of Haematology·Christopher MasonSteven L Allen
Oct 21, 2016·Haematologica·Monique C MinnemaSteven P Treon
Dec 14, 2016·The Lancet Oncology·Meletios A DimopoulosUNKNOWN iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia
Dec 28, 2017·American Journal of Hematology·Joshua N GustineJorge J Castillo
Jun 2, 2018·The New England Journal of Medicine·Meletios A DimopoulosUNKNOWN iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia
Jul 26, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven P TreonJorge J Castillo
Dec 14, 2018·Blood·Jorge J CastilloSteven P Treon
Aug 21, 2019·British Journal of Haematology·Jorge J Castillo, Steven P Treon

❮ Previous
Next ❯

Citations

Nov 14, 2021·Molecular Diagnosis & Therapy·Susana Olmedillas-LópezDamián García-Olmo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.